Ponni Subbiah is joining Acadia Pharmaceuticals (NASDAQ: [[ticker:ACAD]]) as chief medical officer and senior vice president, global head of medical affairs. She was most recently CMO at UK opioid manufacturer Indivior; she previously spent about 15 years at Pfizer (NYSE: [[ticker:PFE]]). San Diego-based Acadia has one drug on the market, pimavanserin (Nuplazid), a treatment for hallucinations and delusions associated with Parkinson’s disease psychosis; it is also pursuing approval of the drug in other indications, as well as the development of treatments for other central nervous system disorders.
Author: Sarah de Crescenzo
Sarah is Xconomy's San Diego-based editor. Prior to joining the team in 2018, she wrote about startups, tech and finance at the San Diego Business Journal. Her decade of full-time news experience includes coverage of subjects including campaign finance, crime and courts as a reporter and editor at outlets throughout California, including the Orange County Register.
She earned a bachelor's degree in English Literature at UC San Diego, where she wrote for the student newspaper and played collegiate lacrosse. In 2019, she earned an MBA at UC Irvine.
View all posts by Sarah de Crescenzo
